Tested in different animal models of AD, AADvac1 raised a protective humoral immune response with antibodies that discriminated between normal and pathological tau, reduced the level of neurofibrillary pathology in rat brains and lowered the content of disease-specific hyperphosphorylated tau [308]. Here, MAPT is linked to Alzheimer disease.